Amarin Corp Plc (AMRN)

[Biobillionair]

Why I see Anchor as a non event:

The past few months I have focused my DD on the medical communities perception of need to treat Dyslipdemia. I've found consistent evidence that the treatment of Dyslipdemia will be backed by NIH through ATP 4 guidelines, and Cardiometabolic risk management guidelines in primary care have again been updated in September of this year to match the new ATP 4 guidelines. While none of the official documents are posted, lectures have been given on "proposed" changes.

While I'm certain Anchor will be approved, clinicians will be bound by evidenced based medicine to use the guidelines to best serve their patients. My latest DD shows Vascepa as first line treatment for dyslipidemia, over statins. Something I expect to be echoed in the Ad Com, but if things get "fishy", in the end Amarin will have guidelines and science recommending the treatment of Dyslipdemia with those that have metabolic syndrome to a goal Trig of <150 and LDL of <70. This population is 30 million.


Williams